Lytix Biopharma: Second quarter and first half of 2022 results

OSLO, Norway, Aug. 25, 2022 /PRNewswire/ — Lytix Biopharma, a Norwegian immune-oncology company, today releases its second quarter and first half 2022 results – New encouraging clinical data.

The first six months of 2022 have been fueled by clinical development and clinical data presentations across international conferences alongside seeing our partner Verrica Pharmaceuticals advance its Phase II study evaluating LTX-315 for basal cell carcinoma. For Lytix, the most significant clinical trial development was the completion of the Phase II study evaluating LTX-315 in combination with adoptive therapy (ACT) in soft tissue sarcoma patients. This combination treatment provided meaningful clinical benefit for patients with progressive metastatic soft tissue sarcoma and clearly shows the potential of using LTX-315 in combination with ACT to generate a high number of tumor-specific T cells“, says Dr. Øystein Rekdal, CEO of Lytix Biopharma.

Highlights from the first quarter 2022:     

  • Data from the Phase II ATLAS-IT-04 trial evaluating LTX-315 in sarcoma patients demonstrated proof-of-concept by showing that the compound improved the outcome of adoptive cell transfer treatment by stabilizing the disease in patients with progressive metastatic soft tissue sarcoma.
  • In April, Verrica Pharmaceuticals dosed the first patient in its Phase II study evaluating LTX-315 in basal cell carcinoma (BCC), triggering an initial milestone payment to Lytix.
  • Regulatory process is initiated and ongoing to expand the site network for the ATLAS-IT-05 study to highly recognized sites with intratumoral immunotherapy expertise in three European countries.
  • The preclinical safety testing for LTX-401 has been completed demonstrating a favorable safety profile. Preparations for a Phase I clinical study are progressing according to plan.
  • In April, Lytix received a USD 1 million milestone payment from Verrica following first patient dosed in its Phase II study of LTX-315 for the treatment of basal cell carcinoma.
  • Total operating expenses for the six months ended 30 June 2022 ended at NOK 36.6 million, which is in line with last year’s figures of NOK 36.1 million.

Key figures (unaudited):



 Amounts in NOK thousands    


Q2 2022


Q2 2021


H1 2022


H1 2021


FY 2021



 Total operating income 


10 427


1 640


11 936


23 201


25 827



 Total operating expense


(20 418)


(14 041)


(36 600)


(36 054)


(73 844)



 Loss from operations    


(9 991)


(12 401)


(24 664)


(12 853)


(48 017)



 Loss for the period        


(1 183)


(12 392)


(16 414)


(12 748)


(48 049)





 Property, plant and equipment    







 Cash position at end of the period


177 084


70 950


197 282



 Trade and other receivables  


6 893


162 792


5 680



 Total assets 


184 108


233 742


202 962



 Total equity    


173 967


233 030


189 624



 Total liabilities  


10 141


10 712


13 338



 Total equity and liabilities 


184 108


233 742


202 962


The full report and a presentation is linked to this press release (and available at

The results will be presented in a webcast with CEO Øystein Rekdal, CDO Graeme Currie and CFO Gjest Breistein at 14:30 CEST.

The presentation and subsequent Q&A session will be held in English and may be viewed live. Please register for the presentation at Lytix Biopharma Q2 webcast 25.08.22

A recording of the presentation will be made available on after the presentation.

For more information, please contact:

Ole Peter Nordby 
[email protected]

Lytix Biopharma in brief:

Based in Oslo, Norway, Lytix is a clinical stage biotech company developing novel cancer immunotherapies, an area within cancer therapy that is aimed at activating the patient’s immune system to fight cancer. The company’s technology is based on pioneering research in “host defense peptides” – nature’s first line of defense towards foreign pathogens. Lytix Biopharma’s lead product, LTX-315, is a first-in-class oncolytic molecule representing a new and superior therapeutic principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapies. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens and potent immunostimulants. This mode of action allows cytotoxic T cells to recognize, infiltrate and attack cancer cells.

This information was brought to you by Cision–second-quarter-and-first-half-of-2022-results,c3619658

The following files are available for download:


Cision View original content:

SOURCE Lytix Biopharma AS

Lytix Biopharma: Second quarter and first half of 2022 results WeeklyReviewer

PR Newswire Science News

World Reviewer Staff
World Reviewer Staff
The first logical thought has to be "no way". I'm the World Observer! Ill find and share important news all day.

Latest articles

Earnings Disclosure

WeeklyReviewer earns primarily through affiliates and ads. We don’t encourage anyone to click on ads for any other purpose but your own. We recommend products and services often for our readers, and through many we will earn commissions through affiliate programs.

Related articles